Simultaneous homoharringtonine and interferon-α in the treatment of patients with chronic-phase chronic myelogenous leukemia (pages 2024–2032)
Susan O'Brien, Moshe Talpaz, Jorge Cortes, Jianqin Shan, Francis J. Giles, Stefan Faderl, Deborah Thomas, Guillermo Garcia-Manero, Susie Mallard, Mary Beth Rios, Charles Koller, Steve Kornblau, Michael Andreeff, Anthony Murgo, Michael Keating and Hagop M. Kantarjian
Article first published online: 28 MAR 2002 | DOI: 10.1002/cncr.10436
Forty-seven patients with Philadelphia chromosome (Ph) positive chronic myelogenous leukemia (CML) were treated with a combination of homoharringtonine (HHT) and interferon-α (IFN-α). The complete hematologic response rate was 85%, and the cytogenetic response rate was 66%, with major responses (Ph < 35%) in 49% of patients and complete responses (Ph = 0%) in 21% of patients. The estimated 2-year survival rate was 90%. The outcome of elderly patients was favorable. Toxicities were manageable with dose adjustments (median daily IFN-α dose, 1 MU/m2; median days on HHT, 2 days per month), but anemia was significant and was responsive to erythropoietin.